Inlyta — Competitive Intelligence Brief

Inlyta (axitinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor [EPC]. Area: Oncology.

marketed Kinase Inhibitor [EPC] Mast/stem cell growth factor receptor Kit Oncology

Target snapshot

Inlyta (axitinib) — Pfizer. Inlyta works by blocking the activity of the mast/stem cell growth factor receptor Kit, which is involved in the growth and spread of cancer cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Inlyta TARGET	axitinib	Pfizer	marketed	Kinase Inhibitor [EPC]	Mast/stem cell growth factor receptor Kit	2012-01-01
Rydapt	MIDOSTAURIN	Novartis	marketed	Kinase Inhibitor [EPC]	Mast/stem cell growth factor receptor Kit	2017-01-01
Wayrilz	RILZABRUTINIB	Genzyme Corp	marketed	Kinase Inhibitor [EPC]		2025-01-01
Hernexeos	ZONGERTINIB	Boehringer Ingelheim	marketed	Kinase Inhibitor [EPC]		2025-01-01
Itovebi	INAVOLISIB	Genentech Inc	marketed	Kinase Inhibitor [EPC]		2025-01-01
Romvimza	VIMSELTINIB	Deciphera Pharms	marketed	Kinase Inhibitor [EPC]		2025-01-01
LAZERTINIB	LAZERTINIB		marketed	Kinase Inhibitor [EPC]		2024-01-01

Recent regulatory actions (last 90 days)

• 2026-02-26 — Hernexeos · FDA · approved · US · Boehringer Ingelheim

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kinase Inhibitor [EPC] class)

1. · 12 drugs in this class
2. Pfizer · 7 drugs in this class
3. Novartis · 3 drugs in this class
4. Bayer · 2 drugs in this class
5. Boehringer Ingelheim · 2 drugs in this class
6. AstraZeneca · 2 drugs in this class
7. Beigene Usa Inc · 1 drug in this class
8. BeiGene · 1 drug in this class
9. AbbVie · 1 drug in this class
10. Bristol · 1 drug in this class